Boehringer Ingelheim and Amgen have entered a clinical phase I collaboration to evaluate a potential combination therapy for cancer.

The trial will determine additional therapeutic benefits of using a combination of SOS1::pan-KRAS inhibitor BI 1701963 and Lumakras (sotorasib) in patients living with lung and colorectal cancers.

Lumakras (sotorasib) is a…


The US Food and Drug Administration (FDA) has approved the biologics license application (BLA) of Pfizer and BioNTech for their Covid-19 messenger ribonucleic acid (mRNA) vaccine, Comirnaty, to prevent the disease in individuals aged 16 years or above.

The vaccine is co-developed by BioNTech and Pfizer and is based on…


Merck (MSD) has reported that its Keytruda met the primary goal of recurrence-free survival (RFS) as adjuvant therapy in the Phase III KEYNOTE-716 trial for surgically resected high-risk stage II melanoma patients.

A humanised monoclonal antibody, Keytruda hinders the interaction between programmed death receptor-1 (PD-1) and its ligands, PD-L1 and…


The US Food and Drug Administration (FDA) has issued a safety alert to patients and health care professionals about a higher risk of death in Oncopeptides’ Phase III OCEAN clinical trial of Pepaxto (melphalan flufenamide) plus dexamethasone in multiple myeloma.

The trial is designed to assess Pepaxto versus pomalidomide, both…


Merck (MSD) has reported that Phase III KEYNOTE-522 trial of its anti-PD-1 therapy Keytruda (pembrolizumab) plus chemotherapy showed a statistically significant event-free survival (EFS) in high-risk early-stage triple-negative breast cancer (TNBC) patients.

A humanised monoclonal antibody, Keytruda hinders the interaction between PD-1 and its ligands, PD-L1 and PD-L2, to trigger…


Novartis has reported positive data from the Phase III REACH3 clinical trial, showing that Jakavi (ruxolitinib) substantially enhanced outcomes in steroid-refractory/dependent chronic graft-versus-host disease (GvHD) patients.

An oral, JAK 1 and JAK 2 tyrosine kinases inhibitor, ruxolitinib was licensed by Novartis from Incyte for development and marketing outside the US.


Zydus Cadila has reported positive interim results from the Phase III clinical trial of its plasmid DNA Covid-19 vaccine candidate, ZyCoV-D.

Based on these data, the company is seeking emergency use authorization (EUA) from the Drug Controller General of India (DCGI) for the vaccine.

On administration, ZyCoV-D generates the SARS-CoV-2…


Pfizer has dosed the first subject in a Phase III TALAPRO-3 clinical trial of oral drug talazoparib plus enzalutamide in men with deoxyribonucleic acid damage response (DDR)-deficient metastatic castration-sensitive prostate cancer (mCSPC).

The first participant was dosed at a study centre in Glendale, California, US.

A poly (ADP-ribose) polymerase (PARP)…


Cyclo Therapeutics has initiated subject enrolment in the Phase III TransportNPC study of Trappsol Cyclo to treat Niemann-Pick Disease Type C1 (NPC1), a rare genetic disorder.

A formulation of hydroxypropyl beta-cyclodextrin, Trappsol Cyclo is intended for intravenous administration.

The enrolment initiation comes after Cyclo Therapeutics obtained regulatory and institutional review…


The Center for Cancer and Blood Disorders (The CenterTX) in the US is set to deploy Deep Lens’ artificial intelligence (AI)-based clinical trial screening and enrolment solution VIPER.

Using Cloud-based technology, VIPER will facilitate, triage, and accelerate the clinical trial recruitment process.

Through its partnership with Deep Lens, The CenterTX…

MEMA - Clinical Trials

An initiative from Eshmoun Company conducting Clinical Research in African–Middle east region.

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store